Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of ...

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAP ...

Among adults with hereditary angioedema, the safety of navenibart up to 24 months was favorable, according to interim trial ...

Unlike current treatments on the market for hereditary angioedema, navenibart requires dosing only every 3-6 months.

USA: Switching to garadacimab may provide a safe and effective option for preventing hereditary angioedema (HAE) attacks, according to interim findings from an ongoing Phase 4 clinical study. Patients ...

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its sebetralstat clinical trial program presented ...

(BPT) - In the U.S., about 7,000 people live with hereditary angioedema, or HAE, 1,2 a rare condition that results in unpredictable swelling attacks. 3-8 Symptoms often appear early in life and can ...

(BPT) - In the U.S., about 7,000 people live with hereditary angioedema, or HAE, 1,2 a rare condition that results in unpredictable swelling attacks. 3-8 Symptoms often appear early in life and can ...

Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and ...

Patients with hereditary angioedema report significant unmet needs, including high costs and insurance barriers, according to data from AAAAI 2026.